Guidance for Industry on Using Electronic Means to Distribute Certain Product Information; Availability, 26102-26103 [E6-6705]
Download as PDF
26102
Federal Register / Vol. 71, No. 85 / Wednesday, May 3, 2006 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Summaries of Medical and Clinical
Pharmacology Reviews of Pediatric
Studies; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
jlentini on PROD1PC65 with NOTICES
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of summaries of medical
and clinical pharmacology reviews of
pediatric studies submitted in
supplements for AGRYLIN (anagrelide),
ARGATROBAN (argatroban), CLOLAR
(clofarabine), and MERIDIA
(sibutramine). These summaries are
being made available consistent with
the Best Pharmaceuticals for Children
Act (BPCA). For all pediatric
supplements submitted under the
BPCA, the BPCA requires FDA to make
available to the public a summary of the
medical and clinical pharmacology
reviews of the pediatric studies
conducted for the supplement.
ADDRESSES: Submit written requests for
single copies of the summaries to the
Division of Drug Information (HFD–
240), Center for Drug Evaluation and
Research, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857. Please specify by
product name which summary or
summaries you are requesting. Send one
self-addressed adhesive label to assist
that office in processing your requests.
See the SUPPLEMENTARY INFORMATION
section for electronic access to the
summaries.
FOR FURTHER INFORMATION CONTACT:
Grace Carmouze, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, rm. 6489,
Silver Spring, MD 20993–0002, 301–
796–2200, e-mail:
grace.carmouze@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
summaries of medical and clinical
pharmacology reviews of pediatric
studies conducted for AGRYLIN
(anagrelide), ARGATROBAN
(argatroban), CLOLAR (clofarabine), and
MERIDIA (sibutramine). The summaries
are being made available consistent with
section 9 of the BPCA (Public Law 107–
109). Enacted on January 4, 2002, the
BPCA reauthorizes, with certain
important changes, the pediatric
exclusivity program described in section
VerDate Aug<31>2005
17:19 May 02, 2006
Jkt 208001
505A of the Federal Food, Drug, and
Cosmetic Act (the act) (21 U.S.C. 355a).
Section 505A of the act permits certain
applications to obtain 6 months of
marketing exclusivity if, in accordance
with the requirements of the statute, the
sponsor submits requested information
relating to the use of the drug in the
pediatric population.One of the
provisions the BPCA added to the
pediatric exclusivity program pertains
to the dissemination of pediatric
information. Specifically, for all
pediatric supplements submitted under
the BPCA, the BPCA requires FDA to
make available to the public a summary
of the medical and clinical
pharmacology reviews of pediatric
studies conducted for the supplement
(21 U.S.C. 355a(m)(1)). The summaries
are to be made available not later than
180 days after the report on the
pediatric study is submitted to FDA (21
U.S.C. 355a(m)(1)). Consistent with this
provision of the BPCA, FDA has posted
on the Internet at https://www.fda.gov/
cder/pediatric/index.htm summaries of
medical and clinical pharmacology
reviews of pediatric studies submitted
in supplements for AGRYLIN
(anagrelide), ARGATROBAN
(argatroban), CLOLAR (clofarabine), and
MERIDIA (sibutramine). Copies are also
available by mail (see ADDRESSES).
II. Electronic Access
Persons with access to the Internet
may obtain the document at https://
www.fda.gov/cder/pediatric/index.htm.
Dated: April 26, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–6706 Filed 5–2–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005D–0385]
Guidance for Industry on Using
Electronic Means to Distribute Certain
Product Information; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a final guidance for
industry entitled ‘‘Guidance for
Industry: Using Electronic Means to
Distribute Certain Product Information’’
dated March 2006. The final guidance
explains that persons can distribute
certain product information, such as for
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
recalls and product safety, by electronic
means. We encourage the use of
electronic communications for
conveying all such important product
safety information. We are making clear
in this guidance that manufacturers and
others may disseminate
communications by electronic means,
including e-mail or other electronic
methods.
DATES: Submit written or electronic
comments on agency guidance
documents at any time.
ADDRESSES: Submit written requests for
single copies of the guidance to the
Office of Policy (HF–11), Office of the
Commissioner, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857. Send one selfaddressed adhesive label to assist that
office in processing your requests.
Submit phone requests to 301–827–
3360. Submit written comments
concerning the guidance to the Division
of Dockets Management (HFA–305),
Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD
20852. Submit electronic comments to
https://www.fda.gov/dockets/ecomments.
See the SUPPLEMENTARY INFORMATION
section for electronic access to the
guidance document.
FOR FURTHER INFORMATION CONTACT:
Jarilyn Dupont, Office of Policy (HF–
11), Office of the Commissioner, Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
3360.
SUPPLEMENTARY INFORMATION:
I. Background
On September 30, 2005, we published
a notice of availability for a draft
guidance entitled ‘‘Guidance for
Industry: Using Electronic Means to
Distribute Certain Product Information’’
(70 FR 57300). The draft guidance
requested comments by November 29,
2005. We received comments from
individuals, associations, companies
that provide safety and drug notices,
and the pharmaceutical industry. We
have reviewed these comments and
have modified the guidance in response
to those comments.
The timely dissemination of
communications about recalls of FDAregulated products, important drug
safety information, and other important
product safety information is essential
for the protection of the public health.
We encourage manufacturers to provide
such information in a timely manner to
distributors, doctors, and others. Over
the years, we have worked with
manufacturers and distributors to
promote the use of electronic methods
of communication and encourage the
E:\FR\FM\03MYN1.SGM
03MYN1
jlentini on PROD1PC65 with NOTICES
Federal Register / Vol. 71, No. 85 / Wednesday, May 3, 2006 / Notices
use of innovative technologies to
disseminate safety information,
particularly when doing so can provide
a public health benefit. We are making
clear in the guidance that manufacturers
and distributors may disseminate the
communications discussed in §§ 7.49
and 200.5 (21 CFR 7.49 and 200.5) by
various electronic methods, including email. The guidance also applies to those
instances, not addressed in any
regulation, where we recommend that
manufacturers and distributors
voluntarily convey certain safety
information about their products to
members of the public.
The use of e-mail and other electronic
communications has dramatically
changed how we and the public convey
information. Electronic communications
have a number of advantages over
paper-based communications. They can
significantly shorten the time between
an event and the public’s knowledge of
the event. When the event involves
product safety, it is even more
important that accurate safety
information be transmitted rapidly. Email and other electronic
communications can be more efficient
and timelier than traditional mail. These
communications involve considerably
less cost to the sender than older, more
traditional delivery services.
Verification of receipt or delivery is less
expensive and can be automatically
accomplished through various means
such as delivery or read receipt
confirmation, or other electronic receipt
acknowledgement mechanisms. Any
necessary followup (such as when
receipt of the e-mail is not
acknowledged in some fashion) also can
be accomplished electronically. If
receipt of the electronic communication
is not acknowledged appropriately by
the recipient (as determined by the
sender) or the electronic communication
is undeliverable, the sender can resort to
more traditional notification methods to
ensure the communication is received.
We interpret the provisions of §§ 7.49
and 200.5 to allow the use of e-mail and
other electronic communication
methods, such as fax or text messaging,
to accomplish any recall notification or
distribution of important safety
information. Section 7.49(b) provides
that, ‘‘A recall communication can be
accomplished by telegrams, mailgrams,
or first class letters* * *’’ Given the use
of the term ‘‘can,’’ we read the three
examples as being illustrative rather
than the sole means of accomplishing
recall communications. Electronic
notification, with appropriate
safeguards and the use of
acknowledgement mechanisms, is a
VerDate Aug<31>2005
17:19 May 02, 2006
Jkt 208001
viable alternative to more traditional
methods.
II. Comments/Responses
We received a number of comments
on the guidance and have modified the
guidance to address some of the
comments. Other comments are outside
the scope of the guidance and thus are
not addressed in the guidance. We have
made changes on our own initiative to
provide clarity to certain statements and
recommendations.
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this guidance.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
III. The Paperwork Reduction Act of
1995
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (the PRA) (44
U.S.C 3501–3520). The collection of
information in this guidance has been
approved under OMB control number
0910–0249 which expires October 18,
2008.
IV. Electronic Access
Persons with access to the Internet
may obtain the document at https://
www.fda.gov/oc/guidance/
electronic.html or https://www.fda.gov/
ohrms/dockets/default.htm.
Dated: April 26, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–6705 Filed 5–2–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
26103
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel,
Information Resources for Radiation Science.
Date: June 8, 2006.
Time: 12 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6130
Executive Blvd., Conference Room C,
Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: Kenneth L. Bielat, PhD,
Scientific Review Administrator, Division Of
Extramural Activities, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, Room 7147, Bethesda,
MD 20892, (301) 496–7576,
bielatk@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel,
Innovations in Cancer Sample Preparation.
Date: June 13, 2006.
Time: 12 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6130
Executive Blvd, Conference Room F,
Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: C. Michael Kerwin, PhD,
MPH, Scientific Review Administrator,
Special Review and Logistics Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 6116 Executive Blvd.,
Rm. 8057, Bethesda, MD 20892–8329, (301)–
496–7421. kerwinm@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Discover
and Development.
Date: June 19–21, 2006.
Time: 6 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Gaithersburg Marriott
Washingtonian Center, 9751 Washingtonian
Boulevard, Gaithersburg, MD 20878.
Contact Person: Peter J. Wirth, PhD,
Scientific Review Administrator, Research
Programs Review Branch, Division of
Extramural Activities, National Cancer
Institute, 6116 Executive Boulevard, Room
8131, Bethesda, MD 20892–8328, 301–496–
7565, pw2q@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, RFA CA–
06–014, ‘‘Tumor Microenvironment
Network’’.
Date: August 2–4, 2006.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\03MYN1.SGM
03MYN1
Agencies
[Federal Register Volume 71, Number 85 (Wednesday, May 3, 2006)]
[Notices]
[Pages 26102-26103]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-6705]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005D-0385]
Guidance for Industry on Using Electronic Means to Distribute
Certain Product Information; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a final guidance for industry entitled ``Guidance for
Industry: Using Electronic Means to Distribute Certain Product
Information'' dated March 2006. The final guidance explains that
persons can distribute certain product information, such as for recalls
and product safety, by electronic means. We encourage the use of
electronic communications for conveying all such important product
safety information. We are making clear in this guidance that
manufacturers and others may disseminate communications by electronic
means, including e-mail or other electronic methods.
DATES: Submit written or electronic comments on agency guidance
documents at any time.
ADDRESSES: Submit written requests for single copies of the guidance to
the Office of Policy (HF-11), Office of the Commissioner, Food and Drug
Administration, 5600 Fishers Lane, Rockville, MD 20857. Send one self-
addressed adhesive label to assist that office in processing your
requests. Submit phone requests to 301-827-3360. Submit written
comments concerning the guidance to the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. Submit electronic comments to https://www.fda.gov/
dockets/ecomments. See the SUPPLEMENTARY INFORMATION section for
electronic access to the guidance document.
FOR FURTHER INFORMATION CONTACT: Jarilyn Dupont, Office of Policy (HF-
11), Office of the Commissioner, Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-3360.
SUPPLEMENTARY INFORMATION:
I. Background
On September 30, 2005, we published a notice of availability for a
draft guidance entitled ``Guidance for Industry: Using Electronic Means
to Distribute Certain Product Information'' (70 FR 57300). The draft
guidance requested comments by November 29, 2005. We received comments
from individuals, associations, companies that provide safety and drug
notices, and the pharmaceutical industry. We have reviewed these
comments and have modified the guidance in response to those comments.
The timely dissemination of communications about recalls of FDA-
regulated products, important drug safety information, and other
important product safety information is essential for the protection of
the public health. We encourage manufacturers to provide such
information in a timely manner to distributors, doctors, and others.
Over the years, we have worked with manufacturers and distributors to
promote the use of electronic methods of communication and encourage
the
[[Page 26103]]
use of innovative technologies to disseminate safety information,
particularly when doing so can provide a public health benefit. We are
making clear in the guidance that manufacturers and distributors may
disseminate the communications discussed in Sec. Sec. 7.49 and 200.5
(21 CFR 7.49 and 200.5) by various electronic methods, including e-
mail. The guidance also applies to those instances, not addressed in
any regulation, where we recommend that manufacturers and distributors
voluntarily convey certain safety information about their products to
members of the public.
The use of e-mail and other electronic communications has
dramatically changed how we and the public convey information.
Electronic communications have a number of advantages over paper-based
communications. They can significantly shorten the time between an
event and the public's knowledge of the event. When the event involves
product safety, it is even more important that accurate safety
information be transmitted rapidly. E-mail and other electronic
communications can be more efficient and timelier than traditional
mail. These communications involve considerably less cost to the sender
than older, more traditional delivery services. Verification of receipt
or delivery is less expensive and can be automatically accomplished
through various means such as delivery or read receipt confirmation, or
other electronic receipt acknowledgement mechanisms. Any necessary
followup (such as when receipt of the e-mail is not acknowledged in
some fashion) also can be accomplished electronically. If receipt of
the electronic communication is not acknowledged appropriately by the
recipient (as determined by the sender) or the electronic communication
is undeliverable, the sender can resort to more traditional
notification methods to ensure the communication is received.
We interpret the provisions of Sec. Sec. 7.49 and 200.5 to allow
the use of e-mail and other electronic communication methods, such as
fax or text messaging, to accomplish any recall notification or
distribution of important safety information. Section 7.49(b) provides
that, ``A recall communication can be accomplished by telegrams,
mailgrams, or first class letters* * *'' Given the use of the term
``can,'' we read the three examples as being illustrative rather than
the sole means of accomplishing recall communications. Electronic
notification, with appropriate safeguards and the use of
acknowledgement mechanisms, is a viable alternative to more traditional
methods.
II. Comments/Responses
We received a number of comments on the guidance and have modified
the guidance to address some of the comments. Other comments are
outside the scope of the guidance and thus are not addressed in the
guidance. We have made changes on our own initiative to provide clarity
to certain statements and recommendations.
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments regarding this guidance.
Submit a single copy of electronic comments or two paper copies of any
mailed comments, except that individuals may submit one paper copy.
Comments are to be identified with the docket number found in brackets
in the heading of this document. Received comments may be seen in the
Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.
III. The Paperwork Reduction Act of 1995
This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (the PRA) (44 U.S.C 3501-
3520). The collection of information in this guidance has been approved
under OMB control number 0910-0249 which expires October 18, 2008.
IV. Electronic Access
Persons with access to the Internet may obtain the document at
https://www.fda.gov/oc/guidance/electronic.html or https://www.fda.gov/
ohrms/dockets/default.htm.
Dated: April 26, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6-6705 Filed 5-2-06; 8:45 am]
BILLING CODE 4160-01-S